In a proactive measure, pharmaceutical company Mylan has announced a voluntary recall affecting 13 lots of EpiPen and EpiPen Jr. devices. This recall is significant given the critical role these devices play for individuals suffering from severe allergic reactions.
According to Mylan’s official statement, the risk associated with the potential defect is low, but the company is taking action to prevent any defective pens from being used. The recall follows reports from outside the U.S. where devices failed to activate because of a defect in a component supplied to Mylan. Notably, the reported failures originated from a single lot that had already been recalled, prompting this broader recall to ensure user safety.
The company emphasized that while the likelihood of encountering a defective device is extremely rare, it is still essential to test and analyze the potentially impacted lots. So far, no defective units have been identified. Should a defect exist, it may hinder the EpiPen’s activation, requiring extra force or potentially failing altogether, which could delay treatment for an allergic reaction.
This recall pertains to devices distributed between December 17, 2015, and July 1, 2016. Consumers are encouraged to verify if their EpiPens are part of the affected lots and to follow Mylan’s guidelines for obtaining replacements. The company advises that individuals retain their current pens until a replacement is provided.
Mylan is no stranger to controversy; the company faced backlash last year over significant price increases for the EpiPen. In response to public outcry, the price was reduced from $600 to $300, although the production cost remains around $30. While the EpiPen continues to be costly, Mylan’s commitment to safety is commendable.
For those interested in related topics, you might find it useful to check out our post on fertility boosters for men at Make a Mom. Additionally, for authoritative insights into successful insemination attempts, visit Intracervical Insemination. For further information on pregnancy and home insemination, Science Daily offers excellent resources.
In summary, Mylan’s voluntary recall of 13 lots of EpiPen devices aims to ensure user safety amid reports of potential activation issues. The company is taking careful measures, encouraging consumers to check their devices and follow replacement procedures.